Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review
Published in: Pharmaceuticals
Access to document
10.3390/ph17060716
document
The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease,...
Domenico Albano, Alessio Rizzo, Riemer H.J.A. Slart, Søren Hess, Edel Noriega-Álvarez, Cristina Gamila Wakfie-Corieh, Lucia Leccisotti, Andor W.J.M. Glaudemans, Olivier Gheysens, Giorgio Treglia
PET/CT in Inflammatory and Auto-immune Disorders: Focus on Several Key Molecular Concepts, FDG, and Radiolabeled Probe Perspectives
Published in: Seminars in Nuclear Medicine
Access to document
10.1053/j.semnuclmed.2023.10.005
document
Chronic immune diseases mainly include autoimmune and inflammatory diseases. Managing chronic inflammatory and autoimmune diseases has become a significant public health concern, and therapeutic advancements over the past 50 years have been substantial. As therapeutic tools continue to multiply, the challenge now lies in providing each patient with personalized care tailored to the specifics of their condition, ushering in the era of personalized medicine. Precise and holistic imaging is essential in this context to comprehensively map the inflammatory processes in each patient, identify prognostic factors, and monitor treatment...
Florent L Besson, Gaetane Nocturne, Nicolas Noël, Olivier Gheysens, Riemer H J A Slart, Andor W J M Glaudemans
Infective Native Aortic Aneurysm: a Delphi Consensus Document on Treatment, Follow Up, and Definition of Cure
Published in: European Journal of Vascular and Endovascular Surgery
Access to document
10.1016/j.ejvs.2023.12.008
document
Objective: Evidence is lacking to guide the management of infective native aortic aneurysm (INAA). The aim of this study was to establish expert consensus on surgical and antimicrobial treatment and follow up, and to define when an INAA is considered cured. Methods: Delphi methodology was used. The principal investigators invited 47 international experts (specialists in infectious diseases, radiology, nuclear medicine, and vascular and cardiothoracic surgery) via email. Four Delphi rounds were performed, three weeks each, using an online questionnaire with initially 28 statements. The panellists rated the statements...
the Academic Research Consortium of Infective Native Aortic Aneurysm (ARC of INAA), Thomas R. Wyss, Matteo Giardini, Karl Sörelius, Andor W.J.M. Glaudemans, Riemer H.J.A. Slart
Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study
Published in: European Journal of Heart Failure
Access to document
10.1002/ejhf.3186
document
Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Hans L.A. Nienhuis, Peter van der Meer
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
Published in: Diagnostics
Access to document
10.3390/diagnostics14040416
document
BACKGROUND: In metastatic breast cancer (MBC), [ 18F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [ 18F]FDG uptake in corresponding metastases. PATIENTS AND METHODS: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [ 18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [ 18F]FDG uptake was expressed as maximum standardized uptake value (SUV max) and...
IMPACT-Metastatic Breast Consortium, Jorianne Boers, Bertha Eisses, Mieke C Zwager, Jasper J L van Geel, Frederike Bensch, Erik F J de Vries, Geke A P Hospers, Andor W J M Glaudemans, Adrienne H Brouwers, Martijn A M den Dekker, Sjoerd G Elias, Evelien J M Kuip, Carla M L van Herpen, Agnes Jager, Astrid A M van der Veldt, Daniela E Oprea-Lager, Elisabeth G E de Vries, Bert van der Vegt, Willemien C Menke-van der Houven van OordtCarolina P Schröder